株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性リンパ性白血病/リンパ芽球性白血病治療薬市場:G8諸国におけるパイプライン予測&市場予測

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2011 - 2020)

発行 MarketsandMarkets 商品コード 224214
出版日 ページ情報 英文 157 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
急性リンパ性白血病/リンパ芽球性白血病治療薬市場:G8諸国におけるパイプライン予測&市場予測 Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2011 - 2020)
出版日: 2013年12月09日 ページ情報: 英文 157 Pages
概要

急性リンパ性白血病/リンパ芽球性白血病の発症率は0歳から14歳の子供の方が、15歳以上の成人よりも高くなっていますが、成人でも発症します。急性リンパ性白血病/リンパ芽球性白血病市場は、小児と成人のセグメントに区分されます。先進8カ国における急性リンパ性白血病/リンパ芽球性白血病治療薬市場は2015年から2020年にかけて4.0%のCAGRで成長すると予測されています。

当レポートでは、先進8カ国における急性リンパ性白血病/リンパ芽球性白血病治療薬市場について調査分析を行い、市場状況、製品市場、パイプライン製品、競合状況、主要企業のプロファイルなどについてまとめ、概略下記の内容でお届けいたします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 白血病の定義
  • 急性リンパ性白血病
    • リスク因子
    • 急性リンパ性白血病の病期/リスクグループ
    • 診断
    • 白血病の有病率
    • 発症率&死亡率
  • 市場構造
    • 主な治療法

第4章 急性リンパ性白血病市場の力学

  • 市場概要
  • 市場力学
    • 市場成長促進因子
    • 市場成長阻害因子
    • 市場機会
  • 緊急の課題
  • 成功の必要条件

第5章 白血病製品市場

  • 市場概要

第6章 急性リンパ性白血病のパイプライン薬(第3相)

  • イントロダクション

第7章 地域分析

  • イントロダクション
  • 米国
  • カナダ
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 日本

第8章 企業プロファイル(概要、財務、製品ポートフォリオ、成長戦略および発展)

  • Erytech Pharma
  • Genzyme Corporation
  • Talon Therapeutics, Inc. (Spectrum Pharmaceuticals, Inc.)
  • Sigma-Tau Pharmaceuticals, Inc.
  • Pfizer Inc
  • Glaxosmithkline Plc

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PH 1729

The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential as the incidence rate of the disease is increasing all over the globe. The incidence of acute lymphocytic/lymphoblastic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic/lymphoblastic leukemia may also occur in adults. The acute lymphocytic/lymphoblastic leukemia market is segmented into two types-childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia.

The acute lymphocytic/lymphoblastic leukemia therapeutics market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic/lymphoblastic leukemia population is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020. In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.).

In contrast to the growth of the market, the cost of the therapies is majorly restraining the acute lymphocytic/lymphoblastic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020.

Market players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to November 2013.

Scope of the report:

This research report categorizes the acute lymphocytic/lymphoblastic leukemia market in G8 countries into the following segments:

Acute Lymphocytic/Lymphoblastic Leukemia Market, by Drug

  • Existing Regimens/Drugs
    • Hyper-CVAD Regimen
    • CALGB 8811 Regimen
    • Linker Regimen
    • Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
    • Oncaspar
  • Pipeline Drugs (Phase III)
    • Graspa
    • Marqibo
    • Inotuzumab Ozogamicin

Acute Lymphocytic/Lymphoblastic Leukemia Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
  • Japan

Table of Contents

1. Introduction

  • 1.1. Objectives of The Study
  • 1.2. Report Description
  • 1.3. Markets Covered
  • 1.4. Stakeholders
  • 1.5. Research Methodology
    • 1.5.1. Market Size Estimation and Data Triangulation
    • 1.5.2. Market Estimation Model
    • 1.5.3. Key Data Points Taken From Secondary Sources
    • 1.5.4. Assumptions Made For This Report

2. Executive Summary

3. Market Overview

  • 3.1. Defining Leukemia
  • 3.2. Acute Lymphocytic Leukemia
    • 3.2.1. Risk Factors
    • 3.2.2. Stages/Risk Groups of Acute Lymphocytic Leukemia
      • 3.2.2.1. Childhood All
        • 3.2.2.1.1. Standard (LOW) Risk
        • 3.2.2.1.2. High Risk
        • 3.2.2.1.3. Recurrent
      • 3.2.2.2. Adult All
        • 3.2.2.2.1. Untreated Adult All
        • 3.2.2.2.2. Adult All in Remission
        • 3.2.2.2.3. Recurrent Adult All
    • 3.2.3. Diagnosis
      • 3.2.3.1. Biopsy and Bone Marrow Aspiration
      • 3.2.3.2. Complete Blood Count (CBC) and Differential
      • 3.2.3.3. Presence of Philadelphia Chromosome
      • 3.2.3.4. Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis
      • 3.2.3.5. Immunophenotyping Or Phenotyping By Flow Cytometry
      • 3.2.3.6. Polymerase Chain Reaction (PCR)
    • 3.2.4. Leukemia Prevalence
    • 3.2.5. Incidence & Mortality
  • 3.3. Market Structure
    • 3.3.1. Key Therapies
      • 3.3.1.1. Chemotherapy
      • 3.3.1.2. Stem Cell/Bone Marrow Transplant
      • 3.3.1.3. Radiation Therapy

4. Acute Lymphocytic Leukemia Market Dynamics

  • 4.1. Market Overview
  • 4.2. Market Dynamics
    • 4.2.1. Market Drivers
      • 4.2.1.1. Innovative Therapies to Drive The Market For Acute Lymphocytic Leukemia
      • 4.2.1.2. Oncology Is The Largest Therapeutic Market With High Unmet Needs
    • 4.2.2. Market Restraints
      • 4.2.2.1. Costs Associated With The Treatment
      • 4.2.2.2. Adverse Events of Treatment
      • 4.2.2.3. Low Production Capability of Drugs
      • 4.2.2.4. Genericiazation of The Major Drugs
    • 4.2.3. Market Opportunities
      • 4.2.3.1. Limited Players in The Market
      • 4.2.3.2. Leukemia's Underserved Patient Populations offer Potential For Market Growth
  • 4.3. Burning Issues
  • 4.4. Winning Imperatives
    • 4.4.1. Market Expansion Through Multiple Therapeutic Approaches

5. Leukemia Product Market

  • 5.1. Market Overview
    • 5.1.1. Hyper-Cvad Regimen
    • 5.1.2. Calgb 8811 Regimen
    • 5.1.3. Linker Regimen
    • 5.1.4. Nucleoside Metabolic Inhibitors (Clolar + Arranon)
    • 5.1.5. Oncaspar

6. Acute Lymphocytic Leukemia Pipeline Molecules (Phase III)

  • 6.1. Introduction
    • 6.1.1. Graspa
    • 6.1.2. Marqibo
    • 6.1.3. Inotuzumab Ozogamicin

7. Geographic Analysis

  • 7.1. Introduction
  • 7.2. U.S.
  • 7.3. Canada
  • 7.4. U.K.
  • 7.5. Germany
  • 7.6. France
  • 7.7. Italy
  • 7.8. Spain
  • 7.9. Japan

8. Company Profiles (Overview, Financials, Products Portfolio, Growth Strategy, and Developments)*

  • 8.1. Erytech Pharma
  • 8.2. Genzyme Corporation
  • 8.3. Talon Therapeutics, Inc. (Spectrum Pharmaceuticals, Inc.)
  • 8.4. Sigma-Tau Pharmaceuticals, Inc.
  • 8.5. Pfizer Inc
  • 8.6. Glaxosmithkline Plc

*Details On Financials, Products Portfolio, Growth Strategy, and Developments Might Not Be Captured in Case of Unlisted Companies.

Competetive Developments (2008 - 2013)

  • Acquisitions/Collaborations/Partnerships/ Agreements/Joint Ventures, 2008 - 2013
  • New Product Launches, 2008 - 2013
  • Expansions/New Facilities/investments, 2008 - 2013 152
  • Approvals, 2008 - 2013
  • Developments Related to Clinical Trials, 2008 - 2013 154
  • Other Developments, 2008 - 2013

List Of Tables

  • Table 1: Yearly Cost of Drugs in North America & Japan, 2013 ($)
  • Table 2: Yearly Cost of Drugs in European Countries, 2013 ($)
  • Table 3: Dosage Pattern of All Drugs
  • Table 4: Acute Lymphocytic Leukemia Drugs: Patent Status
  • Table 5: Acute Lymphocytic Leukemia Drugs: Market Revenue, By Type, 2011 - 2020 ($Million)
  • Table 6: Acute Lymphocytic Leukemia Drugs/Regimens Market Revenue, 2011 - 2020 ($Million)
  • Table 7: Acute Lymphocytic Leukemia Regimen (Hyper-Cvad) Market Revenue, By Country, 2011 - 2020 ($Million)
  • Table 8: Acute Lymphocytic Leukemia Regimen (Calgb 8811) Market Revenue, By Country, 2011 - 2020 ($Million)
  • Table 9: Acute Lymphocyitc Leukemia Drugs (Linker Regimen) Market Revenue, By Country, 2011 - 2020 ($Million)
  • Table 10: Acute Lymphocytic Leukemia Drug Class (Nucleoside Metabolic Inhibitors) Market Revenue, By Country, 2011 - 2020($Million)
  • Table 11: Acute Lymphocytic Leukemia Drugs (Oncaspar) Market Revenue, By Country, 2011 - 2020 ($Million)
  • Table 12: Product Pipeline Molecules: Phase Iii For Acute Lymphocytic Leukemia
  • Table 13: Acute Lymphocytic Leukemia Drugs - Pipeline (Graspa): Market Revenue, By Country, 2015 - 2020 ($Million)
  • Table 14: Acute Lymphocytic Leukemia Drugs - Pipeline (Marqibo): Market Revenue, By Country, 2013 - 2020 ($Million)
  • Table 15: Acute Lymphocytic Leukemia Drugs - Pipeline (Inotuzumab Ozogamicin): Market Revenue, By Country, 2015 - 2020 ($Million)
  • Table 16: Acute Lymphocytic Leukemia Market in G8 Countries, By Geography, 2011 - 2020 ($Million)
  • Table 17: U.S.: Acute Lymphocytic Leukemia Epidemiology, 2011 - 2020
  • Table 18: U.S.: Acute Lymphocytic Leukemia - Existing Regimens/Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 19: U.S.: Acute Lymphocytic Leukemia - Pipeline Drugs Market Revenue, 2012 - 2020 ($Million)
  • Table 20: Canada: Acute Lymphocytic Leukemia Epidemiology, 2011 - 2020
  • Table 21: Canada: Acute Lymphocytic Leukemia - Existing Regimens/Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 22: Canada: Acute Lymphocytic Leukemia - Pipeline Drugs Market Revenue, 2012 - 2020 ($Million)
  • Table 23: U.K.: Acute Lymphocytic Leukemia Epidemiology, 2011 - 2020
  • Table 24: U.K.: Acute Lymphocytic Leukemia - Existing Regimens/Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 25: U.K.: Acute Lymphocytic Leukemia - Pipeline Drugs Market Revenue, 2012 - 2020 ($Million)
  • Table 26: Germany: Acute Lymphocytic Leukemia Epidemiology, 2011 - 2020
  • Table 27: Germany: Acute Lymphocytic Leukemia - Existing Regimens/ Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 28: Germany: Acute Lymphocytic Leukemia - Pipeline Drugs Market Revenue, 2012 - 2020 ($Million)
  • Table 29: France: Acute Lymphocytic Leukemia Epidemiology, 2011 - 2020
  • Table 30: France: Acute Lymphocytic Leukemia - Existing Regimen/ Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 31: France: Acute Lymphocytic Leukemia - Pipeline Drugs Market Revenue, 2012 - 2020 ($Million)
  • Table 32: Italy: Acute Lymphocytic Leukemia Epidemiology, 2011 - 2020
  • Table 33: Italy: Acute Lymphocytic Leukemia - Existing Regimens/Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 34: Italy: Acute Lymphocytic Leukemia - Pipeline Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 35: Italy: Acute Lymphocytic Leukemia - Pipeline Drugs Market Share, 2015 Vs. 2020
  • Table 36: Spain: Acute Lymphocytic Leukemia Epidemiology, 2011 - 2020
  • Table 37: Spain: Acute Lymphocytic Leukemia - Existing Regimens/ Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 38: Spain: Acute Lymphocytic Leukemia - Pipeline Drugs Market Revenue, 2012 - 2020 ($Million)
  • Table 39: Japan: Acute Lymphocytic Leukemia Epidemiology, 2011 - 2020
  • Table 40: Japan: Acute Lymphocytic Leukemia - Existing Regimens/ Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 41: Japan: Acute Lymphocytic Leukemia - Pipeline Drugs Market Revenue, 2011 - 2020 ($Million)
  • Table 42: Erytech Pharma: Product Pipeline
  • Table 43: Erytech: Total Operating Revenue and R&D Expenditure, 2010 - 2012 ($Million)
  • Table 44: Genzyme Corporation: Product Portfolio
  • Table 45: Genzyme Corporation: Total Revenue and R&D Expenditure, 2008 - 2010 ($Million)
  • Table 46: Talon Therapeutics, inc.: Pipeline Product Portfolio
  • Table 47: Talon Therapeutics, inc.: Total R&D Expenditure, 2008 - 2012 ($Million)
  • Table 48: Sigma - Tau Group: Total Revenue, 2008 - 2012 ($Million)
  • Table 49: Pfizer, inc.: Total Revenue and R&D Expenditure, 2008 - 2012 ($Million)
  • Table 50: Galxosmithkline PLC: Total Revenue & R&D Expenses, 2008 - 2012 ($Million)

List Of Figures

  • Figure 1: Acute Lymphocytic Leukemia Market in G8 Countries, By Existing Regimens/Drugs ($Million)
  • Figure 2: Acute Lymphocytic Leukemia Market in G8 Countries, By Product Pipeline ($Million)
  • Figure 3: Status of Acute Lymphocytic Leukemia Product Pipeline
  • Figure 4: Acute Lymphocytic Leukemia Market, By Country
  • Figure 5: Most Common Types of Leukemia
  • Figure 6: Total Leukemia Population, By Country, 2008 - 2020
  • Figure 7: Acute Lymphocytic Leukemia: Age At Diagnosis
  • Figure 8: Stages and Phases of Acute Lymphocytic Leukemia
  • Figure 9: Acute Lymphocytic Leukemia: Population, By Country, 2008 - 2020
  • Figure 10: Market Revenue, By Top 10 Therapeutic Class ($Billion)
  • Figure 11: Erytech and Talon: Product Pipeline
  • Figure 12: Acute Lymphocytic Leukemia Existing Regimens/Drugs Market Share, By Types, 2013 Vs 2015 Vs 2020
  • Figure 13: Acute Lymphocytic Leukemia Pipeline Regimens/Drugs Market Share, By Types, 2015 Vs 2020
  • Figure 14: U.S.: Acute Lymphocytic Leukemia - Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020 ($Million)
  • Figure 15: U.S: Acute Lymphocytic Leukemia - Pipeline Drugs Market Share, 2015 Vs. 2020
  • Figure 16: Canada: Acute Lymphocytic Leukemia - Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
  • Figure 17: Canada: Acute Lymphocytic Leukemia - Pipeline Drugs Market Share, 2015 Vs. 2020
  • Figure 18: U.K.: Acute Lymphocytic Leukemia - Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
  • Figure 19: U.K.: Acute Lymphocytic Leukemia - Pipeline Drugs Market Share, 2015 Vs. 2020
  • Figure 20: Germany: Acute Lymphocytic Leukemia - Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020
  • Figure 21: Germany: Acute Lymphocytic Leukemia - Pipeline Drugs Market Share, 2015 Vs. 2020
  • Figure 22: France: Acute Lymphocytic Leukemia - Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020
  • Figure 23: France: Acute Lymphocytic Leukemia - Pipeline Drugs Market Share, 2015 Vs. 2020
  • Figure 24: Italy: Acute Lymphocytic Leukemia - Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
  • Figure 25: Spain: Acute Lymphocytic Leukemia - Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
  • Figure 26: Spain: Acute Lymphocytic Leukemia - Pipeline Drugs Market Share, 2015 Vs. 2020
  • Figure 27: Japan: Acute Lymphocytic Leukemia - Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020
  • Figure 28: Japan: Acute Lymphocytic Leukemia - Pipeline Drugs Market Share, 2015 Vs. 2020
Back to Top